Big Pharma bets on AI to speed up clinical trials
By Natalie Grover and Martin Coulter LONDON (Reuters) - Major drugmakers are using…
N2:PHAR1
J&J expects double-digit 2023 profit growth after Kenvue spinoff
(Reuters) -Johnson & Johnson on Wednesday forecast double-digit profit growth for…
US FTC suspends challenge to block Amgen’s $27.8 billion deal…
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of…
US FDA puts Gilead Sciences blood cancer drug studies on hold
(Reuters) -Gilead Sciences said on Monday the U.S. health regulator placed a clinical…
Gilead quarterly profit falls on COVID sales drop, legal settlement…
By Michael Erman (Reuters) -Gilead Sciences on Thursday reported lower second-quarter…
AbbVie trims forecast for Humira sales drop on favorable coverage
By Leroy Leo and Patrick Wingrove (Reuters) -AbbVie on Thursday trimmed its 2023 view for…
J&J starts share exchange offer for consumer health spin-off…
(Reuters) -Johnson & Johnson said on Monday it had launched an exchange offer under…
J&J upbeat on 2023 as devices rebound post-COVID, shares jump
By Bhanvi Satija and Patrick Wingrove (Reuters) -Johnson & Johnson on Thursday…
US FTC seeks additional info on Pfizer’s proposed takeover of…
(Reuters) -The US Federal Trade Commission (FTC) has sought additional information and…
Jurors urged to impose heavy punitive damages in J&J talc trial
By Brendan Pierson (Reuters) - Lawyers for a California man who says he developed a rare…